CSIMarket
 
Cytokinetics Incorporated  (CYTK)
Other Ticker:  
 
 

Cytokinetics Incorporated Income Statement Quarterly

CYTK


Select the Financial Report:   Period:   Fiscal Year:

INCOME STATEMENT
(Quarterly GAAP In millions $)

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Revenue From Contract With Customer Excluding Assessed Tax 0.38 0.87 4.61 2.52
Research And Development Revenues From Related Parties - - - -
Research And Development Grant And Other Revenues - - - -
License Revenues From Related Parties - - - -
Related Party Research And Development Revenue - - - -
Research And Development Grant And Other Revenues Net - - - -
Research And Development Milestone Grant And Other Revenues Net - - - -
Total Revenue 0.38 0.87 4.61 1.96 2.52
Cost of Revenues - - - - -
Gross Profit 0.38 0.87 4.61 1.96 2.52
Selling, Administration, Marketing 40.11 39.72 49.67 53.97 48.22
Depriciation & Amortization - - - - -
Research and Development Expense 82.53 83.19 79.42 75.02 62.73
Restructuring, Accretion & impairment charges - - - - -
Other operatinig exp. /-income - 0.00 - - -
Unusual Expense /-Income - - - - -
Total operating costs including COS 122.64 122.92 129.09 128.99 110.96
Operating income/-loss -122.27 -122.05 -124.47 -127.03 -108.44
Other Deductions / - Income
Interest expense 7.14 7.05 6.96 7.06 6.80
Interest income - - - - -
Net interest expense/-income 7.14 7.05 6.96 7.06 6.80
Extinguishment of Debt - - - 2.69 -
Loss/ -Gain on Investment - - - - -
Foreign Currency Transaction (Gain) Loss - - - - -
Allowances, Health Care Trust Fund And Other - - - - -
Unexpected (Gain) Loss - - - - -
Other loss/ -income 0.02 -0.46 -0.15 -33.84 4.82
Non Cash Interest Expense On Liability Related To Sale Of Future Royalties - - - 31.74 -
Gain Loss On Extinguishment And Repurchase Of Debt Instrument - - - 2.69 22.25
Total costs & expenses 129.80 129.50 135.90 139.34 144.83
Income /-loss before income taxes -129.42 -128.64 -131.29 -137.38 -142.31
Income taxes expenses/-benefit - - - - -
Income after income taxes -129.42 -128.64 -131.29 -137.38 -142.31
Net income/-loss of other equity - - - - -
Income/-loss from cont. Ops. -129.42 -128.64 -131.29 -137.38 -142.31
Accounting change - - - - -
Discontinued operations - - - - -
Extraordinary items - - - - -
Net Income/-loss -129.42 -128.64 -131.29 -137.38 -142.31
Noncontrolling interests - - - - -
Prefered dividends - - - - -
Other - - - - -
Income/-loss to shareholder -129.42 -128.64 -131.29 -137.38 -142.31
EBIT -122.29 -121.59 -124.33 -130.32 -135.51
EBITD -120.43 -119.74 -122.48 -128.67 -134.10
EBITDA -120.43 -119.74 -122.48 -128.67 -134.10


Per Share (GAAP Quarterly, in $) (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Basic EPS (excl. extra items) -1.35 -1.34 -1.38 -1.45 -1.52
   Extraordinary items 0.00 0.00 0.00 0.00 0.00
Basic Net EPS -1.35 -1.34 -1.38 -1.45 -1.52
Basic shares outstanding (Mill. of Units) 95.87 96.00 95.14 94.83 93.76
   EPS other shares - - - - -
Diluted Net EPS -1.35 -1.34 -1.38 -1.27 -1.52
Diluted average shares (Mill. of Units) 95.87 96.00 95.14 89.83 93.76
Dividend per share - - - - -



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com